## **UC Irvine UC Irvine Previously Published Works**

## **Title**

Lipidomic Analysis of Biological Samples by Liquid Chromatography Coupled to Mass Spectrometry

**Permalink** <https://escholarship.org/uc/item/7k55w8f6>

## **Authors**

Astarita, Giuseppe Ahmed, Faizy Piomelli, Daniele

## **Publication Date**

2009

## **DOI**

10.1007/978-1-60761-322-0\_10

## **Copyright Information**

This work is made available under the terms of a Creative Commons Attribution License, availalbe at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

# Chapter 10

## Lipidomic Analysis of Biological Samples by Liquid Chromatography Coupled to Mass Spectrometry

**Giuseppe Astarita, Faizy Ahmed, and Daniele Piomelli**

#### **Summary**

Lipidomics studies the large-scale changes in nonwater-soluble metabolites (lipids) accompanying perturbations of biological systems. Because lipids are involved in crucial biological mechanisms, there is a growing scientific interest in using lipidomic approaches to understand the regulation of the lipid metabolism in all eukaryotic and prokaryotic organisms. Lipidomics is a powerful tool in system biology that can be used together with genomics, transcriptomics, and proteomics to answer biological questions arising from various scientific areas such as environmental sciences, pharmacology, nutrition, biophysics, cell biology, physiology, pathology, and disease diagnostics. One of the main challenges for lipidomic analysis is the range of concentrations and chemical complexity of different lipid species. In this chapter, we present a lipidomic approach that combines sample preparation, chromatographic, and intrasource ionization separation coupled to mass spectrometry for analyzing a broad-range of lipid molecules in biological samples.

**Key words:** Lipidomics, Lipids, Liquid chromatography mass spectrometry, Fatty acids, Phospholipids, Cholesterol, Lipid profile, Lipid biomarkers, Large-scale analysis

#### **1. Introduction**

Lipids are natural molecules that are insoluble or partially soluble in water. These hydrophobic or amphipathic molecules can be either biosynthesized or absorbed from the environment and are vital for the life of all eukaryotic and prokaryotic organisms. Lipids play crucial biological roles through three general mechanisms (1) they affect the cellular membrane structures and protein–membrane interactions, (2) they provide a source of energy through processes of oxidation, and (3) they serve as signaling molecules, binding to

DOI 10.1007/978-1-60761-322-0\_10, © Humana Press, a part of Springer Science+Business Media, LLC 2009

Donald Armstrong (ed.), *Lipidomics,* Methods in Molecular Biology, vol. 579,

plasma membrane or nuclear receptors mediating transmembrane signaling and cell-to-cell communication *(1)*.

The development of mass spectro-metry (MS) techniques marked the beginning of a new era for the study of lipids, opening a series of unprecedented experimental opportunities. Indeed, the implementation of atmospheric-pressure ionization techniques such as electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI), capable of coupling liquid chromatography (LC) with MS, made it possible to separate and analyze even the most hydrophobic lipids with much greater accuracy than ever before possible.

Such technological advances have contributed to the advancement of lipidomics, the discipline that studies the largescale changes in lipid composition accompanying perturbations of biological systems (*see* **Note 1**). The ultimate goal of lipidomics is to understand the role of lipids in the biology of living organisms. It represents a rapidly evolving tool in system biology, which integrates multidisciplinary sets of data derived from molecular-profiling techniques such as genomics, transcriptomics, and proteomics. Therefore, there is a growing scientific interest in using lipidomics to answer various biological questions, arising from living organisms with all degree of biological complexity, such as animals, plants, fungi, protists, bacteria, archaea, and viruses. Lipidomic approaches can be used to investigate the following main research areas:

- Lipidomics can be applied to study the impact of both abiotic environmental factors (e.g., climate, radiation, toxins, gravity, CO<sub>2</sub> and oxygen levels, insolation, light-dark cycle, habitat) and biotic environmental factors (e.g., plants, animals, pathogens, and micro-organisms) on lipid metabolism *(2–5)*. *1.1. Ecophysiology*
- Lipidomics is applied to study the effect of nutrients (e.g., carbohydrates, fats, proteins, vitamins, minerals, water, and beverages), nutraceuticals (e.g., antioxidants, fibers, omega-3 fats), food additives and fertilizers on lipid metabolism *(6, 7)*. *1.2. Nutrition*
- Lipidomics can be utilized to study the effects of pharmacological treatments (e.g., medications, vaccinations) and other synthetic products (e.g., cosmetics, contaminants, drugs of abuse, chemicals) on lipid metabolism *(9, 10)*. *1.3. Pharmacology and Toxicology*

Lipidomic approaches can be used to study the effects of genetic diversity (e.g., genotypes, epigenetic regulation, mutations, and polymorphism), messenger RNA expression profiles and protein diversity (e.g., isoforms, post-translational modifications, cofactors) on lipid metabolism. Furthermore, lipidomics can be applied to investigate the biological functions of genes and proteins by *1.4. Genetics, Transcriptomics, and Proteomics*

studying the lipid profiles associated with genetic manipulation (i.e., gene overexpression or knock down) in biological systems. Indeed, fluctuations in lipid composition can be used to uncover alterations in the transcriptome and proteome *(11, 12)*.

- Lipidomic approaches can be used to investigate the effects of lipid composition on biophysical parameters (e.g., fluidity, compressibility), the biological functions of membrane structures (e.g., lipid rafts), as well as lipid–protein and lipid–nucleic acid interactions *(13)*. *1.5. Biophysics*
- Lipidomics can study the role of lipid metabolism in critical cellular processes (e.g., cell cycles, survival/death, morphology, organelles) together with the circadian regulation of biological processes (e.g., development, aging, hormone production, hunger, thirsty, sleep) *(14–17)*. *1.6. Cell Biology*
- Lipidomic approaches can be used to understand the biochemical mechanisms for the biosynthesis and the metabolism of lipids in living organisms. In this area of research, lipidomics may lead to the discovery of novel lipid molecular species and lipid-related biochemical pathways (e.g., enzymes, proteins, receptors, and genes) *(18, 19)*. *1.7. Biochemistry and Molecular Biology*
- Lipidomics can be applied to understand the physiological roles played by endogenous lipids in crucial biological processes (e.g., learning and memory, immune response, pain, and inflammation) *(20, 21)*. Also, lipidomic approaches can unveil the role of lipids in the sensory perception (chemoreception, photoreception, mechanoreception, and thermoreception), in mental processes and behavior (e.g., cognition, emotion, personality, social, and sexual behaviors), and physical activity (e.g., exercise) *(22)*. *1.8. Physiology and Psychology*

Lipidomic strategies can be used to investigate the role of lipid metabolism in the pathology of plant and animal diseases. Indeed, epidemiological studies revealed that many human diseases are characterized by specific alterations in lipid metabolism (e.g., cancer, obesity, diabetes, insomnia, depression, stress, trauma, dementia, as well as infectious, cardiovascular, and neurodegenerative diseases) *(23, 24)*. Therefore, lipidomics can be used to profile lipid composition of biological samples for disease diagnosis and drug discovery. In fact, lipid composition can provide a "snapshot" of the biological state of an organism and, consequently, be considerate as an index (biomarker) of healthy or diseased state *(25, 26)*. Furthermore, such lipid biomarkers can serve also as indicators of pharmacologic responses to a therapeutic intervention *(24)*. *1.9. Pathology and Disease Diagnostics*

One of the main challenges of lipidomic analysis is the range of concentrations and chemical complexity of lipid compounds in biological samples *(27)* **(Scheme 1)**. In fact, a comprehensive lipidomic analysis is expected to take into consideration "structural lipids" (e.g., phospholipids, which serve both as building blocks of the cell membranes and as precursors for signaling lipids), "storage lipids" (e.g., triacylglycerols, which are hydrolyzed to produce either energy or signaling lipids) and the less abundant, but equally important, "signaling lipids" (e.g., fatty acids and their derivatives) **(Scheme 1)**. Therefore, there is a need to develop analytical approaches that allow for the comprehensive analysis of structural, storage, and signaling lipids.

In this chapter, we present current methodologies utilized in our laboratory for lipidomic analysis of biological samples. We describe in some detail an analytical approach that combines sample preparation, chromatographic, and intrasource ionization separation coupled to mass spectrometry for analyzing the lipid composition of cells, biological fluids and tissues (*see* **Note 2**).

#### **2. Materials**





Scheme 1. Lipid classes. Chemical classification of lipids. (a) Fatty acyls are fatty acids and their derivatives (oxygenated, amides, esters). (b) Glycerolipids are fatty acid esters of<br>glycerol and comprise mono-, di-, a Scheme 1. Lipid classes. Chemical classification of lipids. **(a)** Fatty acyls are fatty acids and their derivatives (oxygenated, amides, esters). **(b)** Glycerolipids are fatty acid esters of<br>glycerol and comprise mono-, di goid base moiety. (e) Sterol lipids contain a fused four-ring core (27).

Prostaglandin:  $d_4$ -prostaglandin  $E_2$  from Cayman Chemicals (Ann Arbor, MI, USA).

Fatty-acid ethanolamide: heptadecenoylethanolamide (synthesized as previously reported, *see (28)*).

2. *Glycerolipids*

Triacylglycerol: Trinonadecenoin from Nu-Chek Prep;

Diacylglycerol: dinonadienoyl-*sn*-glycerol from Nu-Chek Prep;

Monoacylglycerol: monoheptadecanoyl-*sn*-glycerol from Nu-Chek Prep; d<sub>s</sub>-2-arachidonoyl-*sn*-glycerol from Cayman Chemicals.

3. *Glycerophospholipids*

Phosphatidylethanolamine: 1,2-diheptadecanoyl-*sn*-glycero-3-phosphoethanolamine from Avanti polar Lipids;

Phosphatidylglycerol: 1,2-diheptadecanoyl-*sn*-glycero-3 phosphoglycerol from Avanti Polar Lipids;

Phosphatidylcholine: 1,2-diheptadecanoyl-*sn*-glycero-3 phosphocholine from Avanti Polar Lipids;

Phosphatidylserine: 1,2-diheptadecanoyl-*sn*-glycero-3-phosphoserine from Avanti Polar Lipids;

Phosphatidylinositol: 1,2-dipalmitoyl-*sn*-glycero-3-phosphoinositol from Avanti Polar Lipids.

4. *Sphingolipids*

Ceramide: *N*-Lauroyl-ceramide from Avanti Polar Lipids;

Sphyngomyelin: *N*-Lauroyl-sphingomyelin from Avanti Polar Lipids.

5. *Sterol lipids*

Cholesterol:  $d_7$ -cholesterol from Avanti Polar Lipids.

6. *Solvents and chemicals*

Water, methanol, chloroform (HPLC grade) are purchased from Thermo Fisher Scientific (Somerset, NJ, USA). Acetic acid and ammonium acetate are from Sigma (Saint Louis, Missouri, USA).

#### *2.3. Supplies*

- 1. LC columns.
- 2. Glass Vials (8 ml, 40 ml, 1.5 ml for autosampler and LC analysis).
- 3. Glass pipettes (5 ml, 10 ml).
- 4. Glass Pasteur pipettes.
- 5. Caps with Teflon-liner.
- 6. Conical insert for reducing the volume of the autosampler vials.
- 7. Vial racks.
- 8. Vial trays.
- 9. Dry ice.

## **3. Methods**





Scheme 2. Lipidomic approach. Flow chart of the strategy used for a broad-range analysis of lipids from biological sample. *MAG* monoacylglycerol, *FAE* fatty acid ethanolamide, *LPC* lysophosphatidylcholine, *FA* fatty acid, *oxFA* oxygenated fatty acids, *DAG* diacylglycerol, *TAG* triacylglycerol, *SP* sphingolipid, *PC* phosphatidylcholine, *PE* phosphatidylethanolamine *PS* phosphatidylserine, *PI* phosphatidylinoitol; *PG* phosphatidylglycerol; *PA* phosphatidic acid.

*3.1.2. Tissues*

Tissues are rapidly collected and snap-frozen in liquid  $\mathrm{N}^{\vphantom{\dagger}}_2$ .

- 1. Label 8-ml glass vials according to the number of tissue samples to analyze.
- 2. Add 1 ml of methanol containing the internal standards in each vial, while keeping the vials in ice.
- 3. Weigh the frozen tissues (10–100 mg) (*see* **Note 6**) and transfer them into the previously prepared vials containing methanol with internal standards.
- 4. Homogenize the tissues keeping the vials in an ice bath and collect 20 ml aliquots for protein measurements (*see* **Note 7**).
- 5. Add 2 ml of chloroform and vortex for 10 s.
- 6. Wash with 0.75 ml of water (or better 0.7% KCl solution) and vortex for 10 s (*see* **Note 8**).
- 7. Centrifuge at  $1,000 \times g$  for 10 min at 4<sup>o</sup>C to the mixture into two phases with a protein disk at their interface. The lower phase is mainly chloroform and contains most of the lipids; the upper phase is methanol and water containing more polar metabolites (*see* **Note 9**).



Blood



- 11. 11 Centrifuge at  $1,000 \times g$  for 10 min at 4<sup>o</sup>C.
- 12. Collect the lower phase with a glass Pasteur pipette and transfer to a clean 8-ml glass vial.
- 13. Evaporate the elnates to dryness under  $N_2$  stream.
- 14. Resuspend in 50–80 µl of a solution chloroform/methanol (1:3, vol:vol).
- 15. Prepare 1.5-ml vials with conical glass inserts.
- 16. Transfer the resuspended lipid solution to the 1.5-ml vials with 0.2-ml conical insert and proceed to LC/MS analysis.
- 17. Normalize lipid amount per ml of biological fluid (mol/ml).

Blood can be fractionated in plasma and blood cells, which is made of white blood cells (WBCs) and red blood cells (RBCs). Blood cells are normally discarded when collecting the plasma. However, the same procedure used for plasma collection, also allows the recovery of the buffy coat (mainly WBCs) and the RBCs, which can be used to measure biomarkers for dietary fat *(29)* and diseases *(30)*.

- 1. Fractionate whole blood samples by centrifuging in EDTA at  $1,000 \times g$  for 10 min at 4<sup>o</sup>C. This will separate the blood into an upper plasma layer, a lower RBCs layer, and a thin interface (buffy coat) containing the WBCs.
- 2. Recover the plasma.
- 3. Recover the WBCs, wash with PBS  $(1 \times)$  three times and centrifuge discarding the supernatant; freeze in distilled water  $(1:1,$  vol:vol).
- 4. Recover the RBCs, wash with PBS  $(1 \times)$  three times and centrifuge discarding the supernatant; freeze in distilled water  $(1:1,$  vol:vol).

Mobile phase A is methanol containing 0.25% acetic acid and 5 mM ammonium acetate; mobile phase B is water containing 0.25% acetic acid and 5 mM ammonium acetate. Lipids are identified based on their retention times and MS*<sup>n</sup>* properties. *3.2. LC/MS Analysis of Lipids*

Small lipid molecules are separated using a reversed-phase Zorbax XDB Eclipse C-18 column  $(50 \times 4.6 \text{ mm} \text{ i.d., } 1.8 \text{ µm} \text{ particle})$ size, 80 Å of porous diameter, Agilent Technologies). Detection and analysis is controlled by Agilent Chemstation and Bruker Daltonics software. *3.2.1. Small Lipids Analysis*

1. *Fatty acyls*

Lipids are eluted using a linear gradient from 90% A to 100% B in 2.5 min at a flow rate of 1.5 ml/min with column



Fig. 1. Analysis of small lipids by LC/MS. Representative LC/MS chromatograms of fatty acids extracted from biological samples.

temperature at 40°C. ESI is in the negative mode, capillary voltage is set at –4 kV and fragmentor voltage is 100 V.  $N_2$  is used as drying gas at a flow rate of 13 l/min and a temperature of 350°C. Nebulizer pressure is set at 60 psi. We use commercially available fatty acyls as reference standards. They are analyzed monitoring the mass-to-charge ratio (*m/z*) of the deprotonated molecular ions [M − H]− in the selected-ion monitoring mode **(Fig. 1)**.

Large lipid molecules are separated using a reversed-phase Poroshell 300SB C-18 column  $(2.1 \times 75$  mm i.d., coating layer of 0.25  $\mu$ m on total particle diameter of 5  $\mu$ m, 300 Å of porous diameter, Agilent Technologies). Lipids are identified based on their retention times and MS<sup>n</sup> properties. Detection and analysis is controlled by Agilent Chemstation and Bruker Daltonics software. *3.2.2. Large Lipids Analysis*

1. *Glycerolipids, glycerophospholipids, sphingolipids*

A linear gradient is applied from 85% A to 100% B in 5 min at a flow rate of 1.0 ml/min with column temperature set at 50°C.



Agilent-Technologies, coating layer of 0.25 um on total particle diameter of 5  $\mu$ m) is used (18, 31). This allows for fast flow rates and good peak shapes **(Fig. 2)**. Usually, because of diffusion limits in totally porous silica, large lipid molecules give tailing peaks at high flow rates. However, superficially coated columns allow for faster diffusion at the surface, allowing high flow rates and good peak shape. Indeed, the thin shell allows the slowly diffusing hydrophobic macromolecules and the rigid structures of sterol lipids to rapidly penetrate the superficial packing material (since the solid core prevents further diffusion). To decrease the retention times, a high flow velocity is applied. To decrease mobile phase viscosity and avoid exceeding the column back-pressure limits, a relatively high column temperature is used. A combination of high temperature and high flow velocities improves the separation speed, resulting in better peak shape of the lipid analytes. Notably, lipids are stable at high temperatures using high flow rates *(32)*. Although lipids are separated when differing in a single fatty acyl chain, their combinatorial nature makes only a partial separation of the isomeric species possible **(Fig. 2)**. Therefore, to obtain more information on the lipid structure, LC separation is coupled with MS*<sup>n</sup>* fragmentation data **(Fig. 3)**. Generally, large lipids are detected in the positive ESI mode as sodium or ammonium adducts or as deprotonated molecular ions in the negative mode. For sterol lipids, which are highly hydrophobic and hard to ionize, APCI is used in the positive mode and the protonated molecular ions are detected after loss of water.



Fig. 2. Analysis of large lipids by LC/MS. Representative LC/MS chromatograms of phosphatidylethanolamines (PE) extracted from biological samples.





operators must wear gloves during the procedures to prevent any contaminations by skin surface lipids. Change gloves frequently and keep vials closed or covered with aluminum foil.

#### **4. Notes**

- 1. Because lipids are a set of small-molecule metabolites, lipidomics is considered to be part of metabolomics, which is the large-scale study of all metabolites (both water-soluble and water-unsoluble) in biological organisms. The distinction originated as consequence of the metabolome (complete set of small-molecule metabolite) complexity, which required the development of analytical approaches specific for nonwater soluble metabolites (lipids) *(35)*.
- 2. The described fast lipidomic approach is suitable for the determination of a broad-range of lipid alterations occurring in biological samples. The combination of the chromatographic resolving power in conjunction with the ionization source selection and the mass detection can be used to analyze even the lipids present at very low concentration. In contrast, the direct infusion of the lipid extract into the MS detector is subject to ionization suppression effects and loss of sensitivity and accuracy. Furthermore, because lipids may differ in mass by only two units, a partial chromatographic separation helps avoid the isotopic effects, which affect the actual mass abundance *(36)*.
- 3. Particular attention should be given to sample preparation: It is worth remembering that there is no good LC/MS analysis without a good sample preparation.
- 4. Alternative extraction procedures that use less toxic organic solvents such as methyl-*tert*-butyl ether *(37)*, hexane–isopropanol, and ethyl acetate/ethanol mixtures have been proposed for a wide range of tissues *(38, 39)*. Surprisingly, it is not always made clear in the laboratory environment that methanol and chloroform are toxic and potentially carcinogenic *(38, 40, 41)*. Furthermore, the methanol/ chloroform mixture is extremely irritating to skin and eyes. Therefore, it is particularly important to train students and new laboratory personnel to handle organic solvents with gloves in a chemical fume-hood, avoiding health-hazard by accidental spills, skin contact and breathing of vapors.
- 5. For the recovery of acidic phospholipids such as gangliosides and phosphoinositides, alternative extraction methods have

been suggested which use strong HCl solutions instead of water during the washing step of the Folch procedure<sup>42</sup>.

- 6. Lipid composition is altered during thawing at room temperature. Therefore, to avoid tissue degeneration (1) cells are kept on ice or (2) tissue samples are cut and weighted while still frozen.
- 7. Sometimes it is useful to normalize the lipid levels in tissue samples by protein amount. Indeed, very small amount of tissue are often difficult to weigh without thawing them and, consequently, altering the lipid composition. Therefore, the samples are directly added to methanol (without the weighting step) and prior to extraction, 20 µl aliquots from the homogenate solutions are taken for protein measurements, which can be conducted using the Bradford protein concentration assay (Bio-Rad Laboratories Inc., Hercules, CA, USA) or the BCA protein assay (Pierce, Rockford, IL, USA).
- 8. The lipid extraction requires a ratio of chloroform, methanol, and water of 8:4:3. In these conditions, after centrifugation and phase separation, the approximate proportion of chloroform, methanol, and water in the upper phase is 3:48:47 by volume. In the lower phase, the respective proportion is 86:14:1.
- 9. To avoid contaminations from the upper aqueous phase into the pipette tip during the recovery of the bottom phase, insert the glass Pasteur pipette through the upper phase with gentle positive-pressure (i.e., gentle bubbling). Also, carefully withdraw the bottom phase through the pipette from the bottom of the vial. Furthermore, to avoid the interface or upper phase, it is better not to recover the entire bottom phase, but leaving the last drops (5–10% of the total organic phase) in the vials.

#### **Acknowledgments**

The contribution of the Agilent Technologies/University of California Irvine Analytical Discovery Facility, Center for Drug Discovery and the Agilent Technologies Foundation are gratefully acknowledged. This work was supported by grants from the National Institute of Health (R21DA-022702, R01DK-073955, R01 DA-012413, R01DA-012447, RR274–297/3504008, RR274–305/3505998, 1RL1AA017538 to D.P.).

#### **References**

- 1. Piomelli D, Astarita G, Rapaka R. (2007) A neuroscientist's guide to lipidomics. *Nat. Rev. Neurosci.* **8**, 743–754.
- 2. Welti R, Shah J, Li W, Li M, Chen J, Burke JJ, Fauconnier ML, Chapman K, Chye ML, Wang X. (2007) Plant lipidomics: discerning biological function by profiling plant complex lipids using mass spectrometry. *Front. Biosci*. **12**, 2494–2506.
- 3. Nicholson JK, Holmes E, Wilson ID. (2005) Gut microorganisms, mammalian metabolism and personalized health care. *Nat. Rev. Micro*. **3**, 431–438.
- 4. Kell DB, Brown M, Davey HM, Dunn WB, Spasic I, Oliver SG. (2005) Metabolic footprinting and systems biology: the medium is the message. *Nat. Rev. Micro*. **3**, 557–565.
- 5. Lin CY, Viant MR, Tjeerdema RS. (2006) Metabolomics: Methodologies and applications in the environmental sciences. *J. Pest. S*. **31**, 245–251.
- 6. Whitfield PD, German AJ, Noble PM. (2004) Metabolomics: an emerging post-genomic tool for nutrition. *Br J Nutr*. **92**, 549–555.
- 7. German JB, Roberts M, Watkins SM. (2003) Personal metabolomics as a next generation nutritional assessment. *J. Nutr.* **133**, 4260–4266.
- 8. Han X. (2007) An update on lipidomics: progress and application in biomarker and drug development. *Curr. Opin. Mol. Ther*. **9**, 586–591.
- 9. Rapaka RS. (2005) Targeted lipidomics and drug abuse research. *Prostaglandins Other Lipid Mediat*. **77**, 219–222.
- 10. Jung K, Astarita G, Zhu C, Wallace M, Mackie K, Piomelli D. (2007) A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. *Mol. Pharmacol*. **72**, 612–621.
- 11. Chen C, Shah YM, Morimura K, Krausz KW, Miyazaki M, Richardson TA, Morgan ET, Ntambi JM, Idle JR, Gonzalez FJ. (2008) Metabolomics reveals that hepatic stearoyl-CoA desaturase 1 downregulation exacerbates inflammation and acute colitis. *Cell Metab.* **7**,135–147.
- 12. Epand RM. (2008) Proteins and cholesterolrich domains. *Biochim. Biophys. Acta*. **1778**, 1576–1582.
- 13. Gaspar ML, Aregullin MA, Jesch SA, Nunez LR, Villa-García M, Henry SA. (2007) The emergence of yeast lipidomics. *Biochim. Biophys. Acta*. **1771**, 241–254.
- 14. Rabinowitz JD. Cellular metabolomics of *Escherchia coli*. (2007) *Expert Rev. Proteomics*. **4**, 187–98.
- 15. Meer GV. (2005) Cellular lipidomics. *EMBO J.* **24**, 3159–3165.
- 16. Hunt AN. (2006) Dynamic lipidomics of the nucleus. *J. Cell. Biochem*. **97**, 244–251.
- 17. Astarita G, Ahmed F, Piomelli D. (2008) Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. *J. Lipid Res*. **49**, 48–57.
- 18. Astarita G, Rourke BC, Andersen JB, Fu J, Kim JH, Bennett AF, Hicks JW, Piomelli D. (2006) Postprandial increase of oleoylethanolamide mobilization in small intestine of the Burmese python (Python molurus). *Am. J. Physiol. Regul. Integr. Comp. Physiol*. **290**, R1407–1412.
- 19. Walker JM, Krey JF, Chen JS, Vefring E, Jahnsen JA, Bradshaw H, Huang SM. (2005) Targeted lipidomics: fatty acid amides and pain modulation. *Prostaglandins Other Lipid Mediat*. **77**, 35–45.
- 20. Serhan CN. (2005) Mediator lipidomics. *Prostaglandins Other Lipid Mediat*. **77**, 4–14.
- 21. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR. (2007) Metabolomic mapping of atypical antipsychotic effects in schizophrenia. *Mol. Psychiatry*. **12**, 934–945.
- 22. Adibhatla R, Hatcher J, Dempsey R. (2006) Lipids and lipidomics in brain injury and diseases. *AAPS J*. **8**, E314-E321.
- 23. Wenk MR. (2005) The emerging field of lipidomics. *Nat. Rev. Drug Discov*. **4**, 594–610.
- 24. Ackermann B, Hale J, Duffin K. (2006) The role of mass spectrometry in biomarker discovery and measurement. *Curr. Drug Metab*. **7**, 525–539.
- 25. Fonteh A, Harrington R, Huhmer A, Biringer RG, Riggins JN, Harrington MG. (2006) Identification of disease markers in human cerebrospinal fluid using lipidomic and proteomic methods. *Dis Markers*. **22**, 39–64.
- 26. Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH Jr, Murphy RC, Raetz CR, Russell DW, Seyama Y, Shaw W, Shimizu T, Spener F, van Meer G, VanNieuwenhze MS, White SH, Witztum JL, Dennis EA. (2005) A comprehensive classification system for lipids. *J Lipid Res*. **46**, 839–861.
- 27. Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, Mackie K, Piomelli D. (2007) Food intake regulates oleoylethanolamide formation and

degradation in the proximal small intestine. *J. Biol. Chem.* **282**, 1518–1528.

- 28. Fuhrman BJ, Barba M, Krogh V, Micheli A, Pala V, Lauria R, Chajes V, Riboli E, Sieri S, Berrino F, Muti P. (2006) Erythrocyte Membrane Phospholipid Composition as a Biomarker of Dietary Fat. *Ann. Nutr. Met*. **50**, 95–102.
- 29. Keshavan MS, Mallinger AG, Pettegrew JW, Dippold C. (1993) Erythrocyte membrane phospholipids in psychotic patients. *Psychiatry Res*. **49**, 89–95.
- 30. Kirkland JJ, Truszkowski FA, Dilks CH, Engel GS. (2000) Superficially porous silica microspheres for fast high-performance liquid chromatography of macromolecules. *J. Chromatogr. A*. **890**, 3–13.
- 31. Barroso B, Bischoff R. (2005) LC-MS analysis of phospholipids and lysophospholipids in human bronchoalveolar lavage fluid. *J. Chromatogr. B*. **814**, 21–28.
- 32. Hodson L, Skeaff CM, Wallace AJ, Arribas GLB. (2002) Stability of plasma and erythrocyte fatty acid composition during cold storage. *Clin. Chim. Acta*. **321**, 63–67.
- 33. Lau O, Wong S. (2000) Contamination in food from packaging material. *J. Chromatogr. A*. **882**, 255–270.
- 34. German JB, Gillies LA, Smilowitz JT, Zivkovic AM, Watkins SM. (2007) Lipidomics and lipid profiling in metabolomics. *Curr. Opin. Lipidol*. **18**, 66–71.
- 35. Han X, Gross RW. (2005) Shotgun lipidomics: multidimensional MS analysis of cellular lipidomes. *Expert Rev. Proteomics*. **2**, 253–264.
- 36. Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D. (2008) Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. *J. Lipid Res.* **49**, 1137–1146.
- 37. Hara A, Radin NS. (1978) Lipid extraction of tissues with a low-toxicity solvent. *Anal. Biochem*. **90**, 420–426.
- 38. Lin J, Liu L, Yang M, Lee M. (2004) Ethyl acetate/Ethyl alcohol mixtures as an alternative to Folch reagent for extracting animal lipids. *J. Agric. Food Chem.* **52**, 4984–4986.
- 39. Boorman GA. (1999) Drinking water disinfection byproducts: review and approach to toxicity evaluation. *Environ. Health Perspect.* **107**, 207–217.
- 40. Greim H, Reuter U. (2001) Classification of carcinogenic chemicals in the work area by the German MAK Commission: current examples for the new categories. *Toxicology*. **166**, 11–23.
- 41. Wenk M, Lucast L, Di Paolo G, Romanelli AJ, Suchy SF, Nussbaum RL, Cline GW, Shulman GI, McMurray W, De Camilli P. (2003) Phosphoinositide profiling in complex lipid mixtures using electrospray ionization mass spectrometry. *Nat. Biotechnol*. **21**, 813–817.